ARTIFICIAL INTELLIGENCE
Biomedical Intelligence Automation
Saving $500k+ Annually in Manual Labor Costs
Learn how AE Studio helped BioCentury automate 27 years of expert editorial analysis using LLMs and named-entity recognition, saving $500k+ annually and enabling same-day biomedical intelligence delivery.
"AE Studio produces deliverables with impressive speed. Their dedication, attentiveness, and valuable recommendations enable ongoing collaboration."
David Smiling, CTO, BioCentury
THE CHALLENGE
The problem.
BioCentury is a leading biotech intelligence platform serving pharmaceutical companies and investment clients who depend on timely, structured analysis of biomedical developments. For nearly three decades, their editorial team manually monitored thousands of sources, including press releases, regulatory filings, and research announcements, extracting and structuring critical entities: companies, diseases, molecular targets, mechanisms of action, clinical trial phases, and deal terms.
This process was the backbone of BioCentury's value proposition. Their analysts brought deep domain expertise to every document, applying nuanced judgment built over years of experience. But the scale of biomedical publishing was accelerating faster than any editorial team could match. Thousands of new documents required processing daily, and the cost of maintaining the manual workforce to handle that volume was unsustainable.
The core challenge was not simply automating data extraction. It was replicating the expert judgment of seasoned biomedical analysts, people who understood not just what a document said, but how to classify it, what entities mattered, and how to structure the output to match BioCentury's proprietary database schema. That kind of institutional knowledge is difficult to encode and even harder to automate.
BioCentury needed a system that could ingest unstructured web content at scale, apply expert-level entity recognition and document classification, and deliver structured intelligence outputs that matched what their human analysts would produce, all without sacrificing the accuracy and reliability their clients depended on.
THE SOLUTION
What we built.
Encoding 27 Years of Institutional Knowledge
The foundation of the solution was BioCentury's own history. Their editorial team had spent 27 years developing classification frameworks, entity taxonomies, and editorial judgment that defined what good biomedical intelligence looked like.
We worked with BioCentury's team to systematically capture that knowledge and translate it into training data and classification logic. This meant understanding not just the output format, but the decision-making process behind it: why a document belongs in one category versus another, which entities are worth flagging, and how ambiguous cases should be handled.
The result was a system trained on BioCentury's own standards rather than generic biomedical data, producing outputs that matched their house style and database schema from day one.
Named-Entity Recognition for Biomedical Content
Standard NER models are trained on general text corpora and underperform on biomedical content, which has a specialized vocabulary, complex entity relationships, and dense domain jargon.
We built a custom named-entity recognition pipeline tuned specifically for BioCentury's content types. The system identifies and extracts key entities from press releases and research documents: companies, drug candidates, disease indications, molecular targets, mechanisms of action, clinical trial phases, and partnership or deal structures.
Entity extraction achieves 95%+ accuracy, meeting the quality bar BioCentury's clients expect from their intelligence products.
Document Classification at Scale
Not every document is equally relevant, and relevance itself is context-dependent. A press release about a Phase 2 trial outcome is categorized differently than a licensing deal announcement or a regulatory submission.
The classification system automatically routes incoming content into BioCentury's intelligence categories using the same logic their editorial team applies. Documents that fall outside established categories are flagged for human review rather than forced into an incorrect classification, preserving quality while minimizing analyst time spent on routine categorization.
HTML-to-Structured Data Pipeline
Biomedical intelligence comes in many formats: HTML pages, JavaScript-rendered content, PDFs, and structured data feeds. BioCentury needed to process all of them.
We built an ingestion pipeline that handles heterogeneous web content, normalizing it into structured data that maps to BioCentury's database schema. This includes parsing pharmaceutical pipeline pages with drug names, trial phases, indications, and timelines, as well as extracting narrative content from prose press releases.
The pipeline is designed for reliability. When sources change their format or structure, the system degrades gracefully and flags anomalies for review rather than silently producing malformed output.
AI Editorial Twins
The most technically ambitious component of the project was building what we call AI editorial twins: AI agents that replicate the decision-making patterns of BioCentury's expert analysts.
Rather than applying generic language model capabilities, these systems are calibrated to specific analyst behaviors, including how they prioritize entities, resolve ambiguity, and structure reports. Each editorial twin is trained on the outputs of actual BioCentury analysts, learning to match their judgment rather than approximate it.
This approach means the system does not just extract data mechanically. It applies contextual reasoning, recognizing when a company name refers to an acquirer versus a target, when a molecular target is primary versus secondary, and when a document warrants a more detailed intelligence note.
Real-Time Pipeline for Same-Day Intelligence
Speed is a competitive differentiator in biomedical intelligence. Pharmaceutical companies and investors need to know about trial results, regulatory decisions, and deal announcements as quickly as possible.
The automated pipeline processes incoming content continuously, enabling same-day intelligence delivery from breaking news and research announcements. What previously required analyst time to monitor, extract, and structure can now be delivered to clients within hours of publication.
This real-time capability was not achievable at scale with a manual editorial team. The automation creates a fundamentally different intelligence product: one that is both faster and more comprehensive than what was possible before.
HOW IT WORKS
The details.
Training the System on 27 Years of Expert Judgment
BioCentury's team had spent 27 years developing ways to classify and structure biomedical intelligence. We worked with them to capture that knowledge and encode it into the system. The result is a tool trained on BioCentury's own standards, not generic data, so its outputs match their house style from day one.
Finding the Right Entities in Biomedical Text
Standard entity recognition tools are trained on general text and fail on biomedical content, which has a dense, specialised vocabulary. We built a custom extraction pipeline tuned for BioCentury's content types. It identifies companies, drug candidates, disease indications, molecular targets, clinical trial phases, and deal structures from press releases and research documents with over 95% accuracy.
Routing Documents to the Right Category
Not all documents are the same kind of news. A Phase 2 trial result is categorised differently from a licensing deal or a regulatory submission. The classification system automatically routes incoming documents using the same logic BioCentury's editorial team applies. Documents that do not fit clearly into an established category are flagged for human review rather than forced into the wrong place.
Processing Any Format the Web Throws at It
Biomedical intelligence arrives as HTML pages, JavaScript-rendered content, PDFs, and structured data feeds. We built an ingestion pipeline that handles all of them, normalising the content into structured data that maps to BioCentury's database. When a source changes its format, the system flags the anomaly rather than silently producing bad output.
AI Models That Think Like BioCentury's Analysts
The most ambitious part of the project was building AI systems calibrated to the decision-making style of specific BioCentury analysts. These are not generic language models. Each one is trained on the outputs of actual analysts and learns to apply their judgment. The system does not just extract data mechanically. It applies context, recognising when the same company name refers to a buyer versus a seller, and when a target molecule is primary rather than secondary.
Same-Day Intelligence at a Scale Manual Processes Cannot Match
Pharmaceutical companies and investors need information about trial results and deal announcements as fast as possible. The automated pipeline processes incoming content continuously. What previously required analyst time to monitor, extract, and structure can now reach clients within hours of publication. This speed was not achievable at scale with a manual team.
OUTCOMES
What shipped.
$500k+ saved annually in manual labor costs
95%+ accuracy in automated entity extraction
27 years of institutional knowledge encoded into classification system
Same-day intelligence delivery from breaking biomedical news
Thousands of sources processed continuously via automated pipeline
KEY TAKEAWAYS
What we learned.
- Encoding institutional knowledge is the hardest part of editorial automation. Training on 27 years of BioCentury's own outputs produced a system that matched their standards rather than approximating them.
- Domain-specific NER outperforms general models on biomedical content. Custom training on pharmaceutical and biotech entity types was essential to achieving 95%+ extraction accuracy.
- AI editorial twins preserve quality at scale. Replicating analyst decision-making patterns rather than building generic extractors keeps output quality aligned with client expectations.
- Real-time pipelines change the nature of the intelligence product. Same-day delivery from breaking news is a capability that manual operations fundamentally cannot match at scale.
- Graceful degradation protects data quality. Flagging anomalies for human review rather than forcing malformed outputs into the database preserves the reliability clients depend on.
IN SUMMARY
Bottom line.
In summary, BioCentury's editorial team spent 27 years building the expertise that defines their intelligence product. As a result, the challenge was not replacing that expertise, but extending it beyond what human capacity could support as the volume of biomedical publishing accelerated.
The automated pipeline now handles the high-volume, routine extraction work, freeing analysts to focus on the nuanced, high-value analysis that AI cannot replicate. Furthermore, the $500k+ in annual savings represents labor costs avoided, but the more significant outcome is a scalable intelligence operation capable of delivering comprehensive, same-day coverage of a biomedical landscape that grows more complex every year.
For pharmaceutical companies and investors who depend on timely, accurate biomedical intelligence, the speed and comprehensiveness of the automated system is itself a competitive advantage, one that manual operations could never have delivered.
FAQ
Frequently asked.
How does the AI system maintain the accuracy that BioCentury's pharmaceutical and investment clients expect?
What types of biomedical content does the pipeline process?
How do AI editorial twins differ from standard document processing or extraction systems?
How does automating editorial workflows affect BioCentury's team?
How does the system handle the fast-moving nature of biomedical news?
LET'S TALK
Bring us the hard problem.
We'll bring the team that ships.